MedTrace Logo

Phase III Study of ASP2151 in Herpes Zoster Patients

NCT01959841 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 751

Last updated 2018-11-27

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.

Conditions

  • Herpes Zoster

Interventions

DRUG

ASP2151

200 mg once daily or 400 mg once daily

DRUG

valaciclovir

1000 mg three times daily

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Maruho Co.,Ltd. Kyoto R&D Center · Clinical Development Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-07-31
Completion
2015-07-10

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959841 on ClinicalTrials.gov